Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04719754
Other study ID # VD-WHH
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 1, 2021
Est. completion date December 2022

Study information

Verified date January 2021
Source Assiut University
Contact Doaa Makarem, MSc
Phone +201065312287
Email Doaamakarem5@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Vaginitis among women of childbearing age is well acknowledged as a public health concern due to its high occurrence. Vulvovaginitis is a disorder of the vulva and/or vagina caused by infection, inflammation, or changes in the flora. There are many types of infections that affect the vagina, the most common three types of infection: bacterial vaginosis, trichomoniasis, and candidiasis. Bacterial vaginosis is the most common vaginal infection in women of reproductive age causing thin and milky vaginal discharge with a fishy odor. Trichomoniasis causes a frothy, greenish-yellow discharge with a foul smell. Vaginal Candidiasis is one of the most common fungal infections of the female genital tract and the second most common vaginal infection affecting women of reproductive age (after the bacterial infection worldwide. It affects more than 75% of women at least once in their lifetime, with approximately 50% of them also suffering a single recurrence. About 75% of patients suffering from candidiasis are asymptomatic, but it may be symptomatic with clinical picture characterized by itching, vaginal pain, vulvar burning sensation, dyspareunia, dysuria and mildly unpleasant odor, erythema and vulvar edema, white-yellowish plaques on the walls of the vagina and cervix and cheesy vaginal discharge. The risk of vulvo-vaginal candidiasis increases by 30% during pregnancy also in pregnancy, the presence of vaginitis is related to abortion, intrauterine infection, fetal growth retardation, premature rupture of membranes, preterm birth, low birth weight, puerperal infection, and other adverse pregnancy outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 164
Est. completion date December 2022
Est. primary completion date October 2022
Accepts healthy volunteers No
Gender Female
Age group 19 Years to 40 Years
Eligibility Inclusion Criteria: - At any gestational age - Age of patient: 19-40 Exclusion Criteria: - Women in labor - Women with current vaginal bleeding - Women with current preterm rupture of membrane - Women immunocompromised women - Women patients who refused to participate in the study

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Vaginal swab
The other vaginal swab will be cultured on blood agar, chocolate agar, MacConkey agar and Sabourauds dextrose agar. The cultures will be incubated at 37ºC for 24-96 h or until the colonies appear.

Locations

Country Name City State
Egypt Woman's Health Hospital - Assiut university Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary The prevalence of microorganism in the vaginal discharge during pregnancy. 9 months
See also
  Status Clinical Trial Phase
Completed NCT00324246 - Feasibility Study of the NEW NORMA-SENSE Phase 3
Recruiting NCT05021315 - Vaginal Cleaning Using Povidone Iodine Before CS to Reduce Postoperative Wound Infection Phase 3
Not yet recruiting NCT05997160 - Research on Vaginal Microbiota Evaluation Unified Standards Based on Gram Staining
Recruiting NCT05557318 - Using Micro Electro Mechanical Systems to Detect the Air of Vaginal Discharge N/A
Completed NCT05044156 - Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women
Completed NCT00694928 - Vaginal Infection Study 2 Phase 3
Not yet recruiting NCT05590195 - Effect of PreforPro® on Urinary and Vaginal Health Phase 3
Completed NCT03898726 - Laparoscopic Versus Transvaginal Cuff Closure N/A
Withdrawn NCT01542606 - Performance Proof of Product Developed to Detect Abnormal Vaginal pH N/A
Not yet recruiting NCT05806879 - Impact of Maternity Napkins on the Incidence of Vaginal Infections in the Post-partum Period N/A
Completed NCT02308046 - Multi-Center Study of New Medications to Treat Vaginal Infections Phase 3
Completed NCT02308007 - Multi-Center Study of New Medications to Treat Vaginal Infections Phase 3
Completed NCT02308033 - Multi-Center Study of New Medications to Treat Vaginal Infections Phase 3
Completed NCT01599416 - Influence of U-relax on Vaginal Health Promotion and HPV DNA Test Change From Positive to Negative N/A
Completed NCT03008421 - Oral Probiotics to Reduce Vaginal Group B Streptococcal Colonization in Late Pregnancy N/A
Completed NCT03261804 - Relation Between Internal Vaginal Douching and Vaginal Infections in Intrauterine Contraceptive Device Users
Terminated NCT05788991 - Comparison of Dequalinium Chloride (Fluomizin) vs Oral Metronidazole for the Treatment of Bacterial Vaginosis Phase 4
Completed NCT01843166 - Vaginal Estrogen With Pessary Treatment N/A
Not yet recruiting NCT03532464 - Azithromycin Compared With Doxycycline for Treating Anorectal Chlamydia Trachomatis Infection Concomitant to a Vaginal Infection Phase 4
Completed NCT01055106 - Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis Phase 2